Dual Targeting with EZH2 Inhibitor and STING Agonist to Treat Melanoma
The immunotherapy era has ushered in enormous promise for cancer, largely led by progress in melanoma management. However a significant fraction of melanoma patients suffers early progression or relapse due to treatment resistance. Immunologically cold tumors are often refractory to immunotherapies...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier B.V.
2022
|
| Online Access: | View Fulltext in Publisher |